Abstract 266P
Background
We aimed to report the somatic mutation profiles in Chinese mCRPC patients using blood-based liquid biopsy with next-generation sequencing (NGS), and to investigate associations between NGS results and physician practices in a real-life setting.
Methods
Patients with mCRPC who had clinical, biochemical, or radiologic disease progression and a prostate-specific antigen (PSA) level > 20 ng/mL after first-line systemic therapy were enrolled from 5 centers in Hong Kong. Comprehensive genomic profiling was performed using FoundationOne™ Liquid CDx. NGS results and pre- and post-NGS treatments were analyzed.
Results
This study included 36 patients (median age, 72.5 yr; median PSA, 69.9 ng/mL): 29 (80.6%) had an Eastern Cooperative Oncology Group performance score of 1; one-third had a Gleason score of 9; 28 (77.8%) had symptomatic disease; 7 (19.4%) and 15 (41.7%) received two and three lines of systemic therapies, respectively. Common genomic alterations were found in AR (52.8%), TP53 (44.4%), DNMT3A (33.3%), and BRCA2 (25.0%). Amplification and single-nucleotide variants were detected in 31.6% (6/19) and 47.4% (9/19) of the AR variants, respectively. The most common mutations in homologous recombination repair-related genes were found in BRCA2 (25.0%), CDK12 (19.4%), and ATM (8.3%), at comparable frequencies to those in the PROfound trial (NCT02987543). High microsatellite instability was detected in 2 (5.6%) patients. The overall median tumor mutational burden was 4.0 mut/Mb, 4/9 patients with variant BRCA2 were switched to a poly (ADP-ribose) polymerase (PARP) inhibitor, and all showed clinical benefits. The reasons for not using a PARP inhibitor included poor performance status (n = 2), cost (n = 1), and patient decision (n = 1).
Conclusions
Half of a cohort of Chinese patients with mCRPC who failed first-line therapy had AR mutations. BRCA2 mutations were detected in 9 (25.0%) patients, 4 of whom were switched to a PARP inhibitor and benefited clinically. In a real-life situation, liquid biopsy could potentially impact physician practices as well as patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract